CYTOKINETICS INC
CYTKNASDAQTrading Snapshot
- Day Range
- $65.33 – $66.89
- 52-Week Range
- $47.22 – $88.31
- Volume
- $4.68B
- Avg Volume
- $6.04B
- Shares Outstanding
- 135.6M
- Next Earnings
- Nov 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $88M
- Last Q Revenue
- $32M
- P/E Ratio
- —
- P/S Ratio
- 135.1x
- EPS (TTM)
- $-7.22
- Dividend Yield
- —
- Dilution (1yr)
- +3.7%
Why Investors Own CYTK
- ✓High-growth profile — revenue up +6.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CYTOKINETICS INC
CYTK
StockOtter · stockotter.spaceAbout CYTOKINETICS INC
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
CYTOKINETICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CYTK price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
CYTOKINETICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.